JAK2 and myeloproliferative disorder: For patients with PV in the MPN patient cohort, we did not see significant differentiation between the top and bottom quintiles for blood cell trait PGSs, possibly because the mutant JAK2 clone dominates the PV phenotype in this patient cohort (PV JAK2+ including JAK2het and JAK2hom in Fig. 4b; n = 112), resulting in the PGSs not having an observed impact.